MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $1.18 and traded as high as $1.25. MAIA Biotechnology shares last traded at $1.25, with a volume of 1,822,036 shares trading hands.
MAIA Biotechnology News Summary
These are some of the MAIA news items that stood out recently:
- Positive Sentiment: MAIA reported an 88% disease control rate in the expanded Phase 2 THIO-101 study, evaluating ateganosine as a third-line treatment for advanced NSCLC. The company said the results are consistent with strong efficacy observed in earlier study parts; further Part C data could support an accelerated-approval filing. MAIA reports THIO-101 efficacy data
- Positive Sentiment: The company completed enrollment in the THIO-101 expansion. MAIA has FDA Fast Track designation for ateganosine, while a Phase 3 survival analysis is expected in 2027—milestones that may help clarify the therapy’s development and regulatory prospects. THIO-101 enrollment and survival analysis update
- Positive Sentiment: Diamond Equity raised its projected earnings per share for FY2026 and FY2027, forecasting smaller losses than previously expected. This is a modestly favorable analyst revision, though MAIA is still expected to remain loss-making. MAIA analyst estimates
MAIA Biotechnology Price Performance
The company has a market capitalization of $77.19 million, a PE ratio of -2.66 and a beta of 0.28. The company has a 50 day moving average of $1.18 and a two-hundred day moving average of $1.39.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. On average, equities analysts anticipate that MAIA Biotechnology, Inc. will post -0.48 EPS for the current year.
Insider Activity
In other MAIA Biotechnology news, Director Ramiro Guerrero purchased 78,239 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $1.39 per share, with a total value of $108,752.21. Following the transaction, the director directly owned 689,081 shares in the company, valued at approximately $957,822.59. The trade was a 12.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Vlad Vitoc acquired 73,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average cost of $1.37 per share, for a total transaction of $100,010.00. Following the purchase, the chief executive officer directly owned 1,049,121 shares of the company's stock, valued at $1,437,295.77. This represents a 7.48% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 258,078 shares of company stock valued at $352,426. 19.81% of the stock is owned by company insiders.
Hedge Funds Weigh In On MAIA Biotechnology
A number of institutional investors and hedge funds have recently made changes to their positions in MAIA. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the 3rd quarter worth approximately $100,000. Empowered Funds LLC purchased a new stake in shares of MAIA Biotechnology in the 3rd quarter worth approximately $88,000. StoneX Group Inc. purchased a new stake in shares of MAIA Biotechnology in the 3rd quarter worth approximately $78,000. Susquehanna International Group LLP purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth approximately $51,000. Finally, Cable Car Capital LP bought a new position in MAIA Biotechnology during the 2nd quarter valued at approximately $741,000. Institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company's lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.